LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has introduced Daptomycin for Injection in the United States. Daptomycin for Injection, an antibiotic, is a generic alternative to CUBICIN®. According to IMS, as of July 2016, Daptomycin for injection had sales in the U.S. of approximately $1.2 billion.
Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.
“We are pleased to offer health care professionals and patients a generic alternative to Cubicin,” said John Ducker, president and CEO of Fresenius Kabi USA. “Products like this help make high-quality health care more affordable. Having access to generic alternatives is especially important with a product such as Daptomycin, which is used to fight serious infections resistant to other treatments.”
Fresenius Kabi Daptomycin for Injection is available as a single dose vial containing 500 mg/vial.
Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. Daptomycin is not indicated for the treatment of pneumonia.
CUBICIN® (daptomycin for injection) is a registered trademark of Merck & Co., Inc.
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.
